[go: up one dir, main page]

YU59601A - Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena - Google Patents

Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena

Info

Publication number
YU59601A
YU59601A YU59601A YUP59601A YU59601A YU 59601 A YU59601 A YU 59601A YU 59601 A YU59601 A YU 59601A YU P59601 A YUP59601 A YU P59601A YU 59601 A YU59601 A YU 59601A
Authority
YU
Yugoslavia
Prior art keywords
alkyl
group
hydrogen
preparation
halogen atom
Prior art date
Application number
YU59601A
Other languages
English (en)
Inventor
Frederic Galli
Samir Jegham
Alistair Lochead
Axelle Samson
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of YU59601A publication Critical patent/YU59601A/sh
Publication of RS49997B publication Critical patent/RS49997B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Jedinjenja opšte formule (I) u kojoj je R1 atom vodonika, alkil, fenilalkil, fenilhidroksialkil, furanilalkil ili furanilhidroksialkil grupa, R2 je bio atom vodonika ili halogena ili trifluorometil, cijano, hidroksil, nitro, acetil, alkil, alkoksi ili amino grupa opšte formule NR4R5 u kojoj su R4 i R5 svaka atom vodonika ili alkil grupa ili formiraju sa atomom azota, koji ih nosi, prsten (C4-C7), ili fenil ili naftil grupu, po želji supstituisanu atomom halogena ili trifluorometil, trifluorometoksi, cijano, hidroksil, nitro, acetil, alkil, alkoksi ili metilendioksi grupom, a R3 je atom vodonika ili halogena ili alkil grupa.
YUP-596/01A 1999-03-05 2000-03-01 Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena RS49997B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
YU59601A true YU59601A (sh) 2004-03-12
RS49997B RS49997B (sr) 2008-09-29

Family

ID=9542888

Country Status (37)

Country Link
US (2) US6538003B1 (sh)
EP (1) EP1161434B1 (sh)
JP (1) JP4806123B2 (sh)
KR (2) KR100768355B1 (sh)
CN (1) CN1137894C (sh)
AR (1) AR022820A1 (sh)
AT (1) ATE231869T1 (sh)
AU (1) AU764625B2 (sh)
BG (1) BG65211B1 (sh)
BR (1) BR0008763A (sh)
CA (1) CA2372063C (sh)
CO (1) CO5160250A1 (sh)
CZ (1) CZ302259B6 (sh)
DE (1) DE60001307T2 (sh)
DK (1) DK1161434T3 (sh)
EE (1) EE04497B1 (sh)
ES (1) ES2191611T3 (sh)
FR (1) FR2790474B1 (sh)
HK (1) HK1040398B (sh)
HR (1) HRP20010655B1 (sh)
HU (1) HU228671B1 (sh)
ID (1) ID30116A (sh)
IL (2) IL145150A0 (sh)
MX (1) MXPA01008972A (sh)
NO (1) NO327119B1 (sh)
NZ (1) NZ513561A (sh)
PE (1) PE20001543A1 (sh)
PL (1) PL201683B1 (sh)
RS (1) RS49997B (sh)
RU (1) RU2238273C2 (sh)
SK (1) SK284339B6 (sh)
TR (1) TR200102403T2 (sh)
TW (1) TWI222975B (sh)
UA (1) UA61164C2 (sh)
UY (1) UY26048A1 (sh)
WO (1) WO2000053608A1 (sh)
ZA (1) ZA200106811B (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04012010A (es) 2002-07-18 2005-03-07 Cytos Biotechnology Ag Conjugados de hapteno-portador que comprende particulas similares a virus, y usos de los mismos.
CN102657651A (zh) * 2002-12-06 2012-09-12 范因斯坦医学研究院 用α 7受体结合胆碱能激动剂抑制炎症
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
CN101952276B (zh) * 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途
CA2707671C (en) * 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
JP2011516489A (ja) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
AU2009316557B2 (en) 2008-11-19 2015-08-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
US9040568B2 (en) * 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
CA2799744C (en) 2010-05-17 2020-01-28 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
NZ500643A (en) * 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
BR0008763A (pt) 2002-01-02
DK1161434T3 (da) 2003-05-26
US6908927B2 (en) 2005-06-21
NO327119B1 (no) 2009-04-27
CA2372063A1 (en) 2000-09-14
DE60001307D1 (de) 2003-03-06
HK1040398B (zh) 2003-07-18
PL352330A1 (en) 2003-08-11
IL145150A (en) 2007-06-03
RS49997B (sr) 2008-09-29
HU228671B1 (en) 2013-05-28
FR2790474A1 (fr) 2000-09-08
EE04497B1 (et) 2005-06-15
US6538003B1 (en) 2003-03-25
PL201683B1 (pl) 2009-04-30
JP4806123B2 (ja) 2011-11-02
US20030187012A1 (en) 2003-10-02
HRP20010655B1 (en) 2003-06-30
SK284339B6 (sk) 2005-02-04
ZA200106811B (en) 2002-08-19
BG105828A (bg) 2002-03-29
PE20001543A1 (es) 2001-03-18
UY26048A1 (es) 2000-09-29
UA61164C2 (uk) 2003-11-17
HRP20010655A2 (en) 2002-08-31
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
EP1161434B1 (fr) 2003-01-29
EP1161434A1 (fr) 2001-12-12
SK12422001A3 (sk) 2002-04-04
AR022820A1 (es) 2002-09-04
DE60001307T2 (de) 2003-12-11
CN1137894C (zh) 2004-02-11
EE200100470A (et) 2002-12-16
ES2191611T3 (es) 2003-09-16
CZ20013102A3 (cs) 2002-01-16
HUP0201753A3 (en) 2004-12-28
NO20014270L (no) 2001-11-05
AU764625B2 (en) 2003-08-28
WO2000053608A1 (fr) 2000-09-14
NZ513561A (en) 2003-06-30
TR200102403T2 (tr) 2001-12-21
FR2790474B1 (fr) 2001-04-06
MXPA01008972A (es) 2002-03-27
CA2372063C (en) 2011-01-11
CO5160250A1 (es) 2002-05-30
IL145150A0 (en) 2002-06-30
HUP0201753A2 (en) 2002-09-28
KR20010102492A (ko) 2001-11-15
ATE231869T1 (de) 2003-02-15
TWI222975B (en) 2004-11-01
JP2002539129A (ja) 2002-11-19
RU2238273C2 (ru) 2004-10-20
ID30116A (id) 2001-11-08
CN1343208A (zh) 2002-04-03
KR100768355B1 (ko) 2007-10-17
NO20014270D0 (no) 2001-09-03
CZ302259B6 (cs) 2011-01-19
KR20070086359A (ko) 2007-08-27
HK1040398A1 (en) 2002-06-07

Similar Documents

Publication Publication Date Title
YU59601A (sh) Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena
DK7280A (da) Fremgangsmaade til fremstilling af (piperidinylalkyl) quinazolin-derivater
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
FI970246A7 (fi) Dihydrobentsofuraanit
CL2004001109A1 (es) Compuestos tien-3-il-sulfonilamino(tio) carbonil-triazolin(tio)onas sustituidas; procedimiento de obtencion; compuestos intermediarios; uso de los compuestos; y agentes herbicidas.
HUP0300382A2 (hu) 2-Szubsztituált-4-heteroaril-pirimidinek és alkalmazásuk proliferatív rendellenességek kezelésében és a vegyületeket tartalmazó gyógyszerkészítmények
DE69929689D1 (de) Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
EA199900121A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов вак
AR013078A1 (es) Derivados de tetrahidroisoquinoleina, una sal de los mismos, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de losmismos en la preparacion de un medicamento.
AR028648A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano-fenilisoxazol, su preparacion y su aplicacion en terapéutica
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
AR028647A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano benzoxazol, benzotiazol y bencimidazol, su preparacion y su aplicacion en terapéutica
HRP20040230B1 (hr) Agonisti muskarina
DK1086096T3 (da) Benzamider med tetrahydrofuranyloxy-substituenter som inhibitorer af phosphodiesterase 4
YU33490A (sh) Antivirusna tetrahidroimidazo (1,4)benzodiazepin-2-tiona jedinjenja i postupak za njihovo dobijanje
FR2682107B1 (fr) Quinoleines 2-substituees pour le traitement des leishmanioses.
NO995289L (no) Benzimidazol-derivater
PL337930A1 (en) Derivatives of benzothiophene as well as their application and compositions
DE69103968D1 (de) 2-(Aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre Herstellung und ihre Anwendung in der Therapeutik.
ATE102199T1 (de) 4-amino-3-carboxynaphthyridin-derivate, ihre herstellung und pharmazeutische zusammensetzungen.
BR9205660A (pt) Derivados de sulfoniluréia processo de sua preparaçào a sua aplicaçào
FI910319A0 (fi) Haorfaergningsmedel.
TR200000057T2 (tr) 6-pirolidin-2-ilpirindinler, hazırlanmaları ve terapötik uygulamaları.
TW334340B (en) Preparation for pyrazolyl derivatives
HUP9902182A2 (hu) 1,3-Ciklohexándion-származékok alkalmazása szelektív kukorica herbicidként